Back to MetLife Investment Management, LLC MetLife Investment Management, LLC

INBXINBX
Showing 8 of 9 quarters

Position history for MetLife Investment Management, LLCMetLife Investment Management, LLC's holdings in INHIBRX BIOSCIENCES INC

Yes. MetLife Investment Management holds 5,638 shares of INBX (Inhibrx Biosciences), worth $534,201, as of its Q2 2026 13F filing. It increased the position by 398 shares (+7.6%) from Q1 2026. MetLife Investment Management has held INBX in every 13F on record since Q2 2024, 9 quarterly filings.

Current Value

$534,201

Current Shares

5,638

Total Value Change

+$442,480

Total Shares Change

-219

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
5,638
+7.6%
$534,2010.0%$94.75
26
2026-Q1
Decreased
5,240
-1.5%
$352,2850.0%$74.33
0
2025-Q4
Decreased
5,320
-28.4%
$420,2800.0%$77.98
0
2025-Q3
Decreased
7,425
-3.4%
$250,0740.0%$32.31
0
2025-Q2
Unchanged
7,683
0.0%
$109,6370.0%$14.43
0
2025-Q1
Unchanged
7,683
0.0%
$107,4850.0%$14.12
0
2024-Q4
Increased
7,683
+31.2%
$118,3180.0%$15.14
28
2024-Q3
Increased
5,857
+21.4%
$91,7210.0%$15.52
26

Other major holders of INBX: MORGAN STANLEY, VIKING GLOBAL INVESTORS LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used